CL2008002860A1 - Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido. - Google Patents

Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido.

Info

Publication number
CL2008002860A1
CL2008002860A1 CL2008002860A CL2008002860A CL2008002860A1 CL 2008002860 A1 CL2008002860 A1 CL 2008002860A1 CL 2008002860 A CL2008002860 A CL 2008002860A CL 2008002860 A CL2008002860 A CL 2008002860A CL 2008002860 A1 CL2008002860 A1 CL 2008002860A1
Authority
CL
Chile
Prior art keywords
polypeptide
polynucleotide
cells
vector
fagtium
Prior art date
Application number
CL2008002860A
Other languages
English (en)
Inventor
Rose Schofield Linley
Dey Debjit
Mary Tootill Catherine
Sang Carrie
Diane Moon Graeme Trevor Attwood William John Kelly Eric Heinz Altermann Sinead Christine Christina
Dong Zhanhao Kong Li
Original Assignee
Pastoral Greenhouse Gas Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pastoral Greenhouse Gas Res Limited filed Critical Pastoral Greenhouse Gas Res Limited
Publication of CL2008002860A1 publication Critical patent/CL2008002860A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/20—Reduction of greenhouse gas [GHG] emissions in agriculture, e.g. CO2
    • Y02P60/22—Methane [CH4], e.g. from rice paddies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

COMPOSICIONES Y MÉTODOS PARA LA ADMINISTRACIÓN DE MOLÉCULAS INHIBIDORAS EN CÉLULAS MICROBIANAS, EN PARTICULAR, CÉLULAS METANÓGENOS Y MÁS ESPECÍFICAMENTE EL PMRU FAGO RECIENTEMENTE IDENTIFICADO, QUE INCLUYE LA INDUCCIÓN DEL FAGO, PARTÍCULAS DEL FAGO, Y EL GENOMA DEL FAGO, Y TAMBIÉN POLIPÉPTIDOS DEL FAGO, ASÍ COMO TAMBIÉN POLINUCLÉOTIDOS QUE CODIFICAN ESTOS POLIPÉPTIDOS. LA INVENCIÓN TAMBIÉN SE REFIERE A VECTORES DE EXPRESIÓN Y CÉLULAS HUÉSPED PARA LA PRODUCCIÓN DE ESTOS POLIPÉPTIDOS Y A MÉTODOS PARA DETECTAR, APUNTAR, E INHIBIR CÉLULAS MICROBIANAS, ESPECIALMENTE CÉLULAS METANÓGENAS, UTILIZANDO EL FAGO REVELADO, POLIPÉPTIDOS, POLINUCLÉOTIDOS, VECTORES DE EXPRESIÓN, Y CÉLULAS HUÉSPED.
CL2008002860A 2007-09-25 2008-09-25 Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido. CL2008002860A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97510407P 2007-09-25 2007-09-25
US98984107P 2007-11-22 2007-11-22
US98984007P 2007-11-22 2007-11-22

Publications (1)

Publication Number Publication Date
CL2008002860A1 true CL2008002860A1 (es) 2009-06-05

Family

ID=40511642

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2008002861A CL2008002861A1 (es) 2007-09-25 2008-09-25 Polipeptido aislado de m. ruminantium; vector, molecula conjugada y celula huesped que comprenden dicho polipeptido; anticuerpo o fragmento que se une al polipeptido; composicion farmaceutica que comprende la molecula conjugada; metodo para dirigir una celula metanogena para identificacion, aislamiento o inhibicion.
CL2008002859A CL2008002859A1 (es) 2007-09-25 2008-09-25 Péptido señal con actividad de permeabilización de células microbianas; vector; célula huésped; molécula conjugada que lo comprende; y método para permeabilizar una célula microbiana.
CL2008002860A CL2008002860A1 (es) 2007-09-25 2008-09-25 Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2008002861A CL2008002861A1 (es) 2007-09-25 2008-09-25 Polipeptido aislado de m. ruminantium; vector, molecula conjugada y celula huesped que comprenden dicho polipeptido; anticuerpo o fragmento que se une al polipeptido; composicion farmaceutica que comprende la molecula conjugada; metodo para dirigir una celula metanogena para identificacion, aislamiento o inhibicion.
CL2008002859A CL2008002859A1 (es) 2007-09-25 2008-09-25 Péptido señal con actividad de permeabilización de células microbianas; vector; célula huésped; molécula conjugada que lo comprende; y método para permeabilizar una célula microbiana.

Country Status (17)

Country Link
US (7) US8592556B2 (es)
EP (5) EP2203467B1 (es)
JP (5) JP5558356B2 (es)
CN (4) CN102015755A (es)
AR (3) AR068551A1 (es)
AU (4) AU2008305846A1 (es)
BR (5) BRPI0817312B1 (es)
CA (3) CA2700164C (es)
CL (3) CL2008002861A1 (es)
DK (3) DK3327030T3 (es)
ES (3) ES2895908T3 (es)
MX (3) MX2010003321A (es)
NZ (2) NZ780936A (es)
RU (1) RU2528854C2 (es)
UY (3) UY31360A1 (es)
WO (3) WO2009041832A2 (es)
ZA (1) ZA201001933B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041832A2 (en) 2007-09-25 2009-04-02 Pastoral Greenhouse Gas Research Ltd Vaccines and vaccine components for inhibition of microbial cells
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
WO2010149795A1 (en) * 2009-06-26 2010-12-29 Lysando Holding Establishment Antimicrobial agents
EA037202B1 (ru) * 2009-06-26 2021-02-18 Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д Слитые белки для лечения инфекций, вызванных грамотрицательными бактериями
UY32866A (es) 2009-08-27 2011-03-31 Pastoral Greenhouse Gas Res Ltd Secuencia genómica completa del metanógeno methanobrevibacter ruminantium
US9534223B2 (en) * 2010-04-27 2017-01-03 Lysando Ag Method of reducing biofilms
ES2802253T3 (es) * 2012-09-19 2021-01-18 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
IL289396B2 (en) 2013-03-15 2023-12-01 The General Hospital Coporation Using tru-grnas to increase the specificity of RNA-guided genome editing
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
US10208298B2 (en) * 2014-11-06 2019-02-19 E.I. Du Pont De Nemours And Company Peptide-mediated delivery of RNA-guided endonuclease into cells
CN104789675A (zh) * 2015-04-15 2015-07-22 江苏师范大学 一种检测荷斯坦奶牛瘤胃微生物的方法
US11845928B2 (en) * 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CN109477065A (zh) * 2016-07-14 2019-03-15 巴斯夫欧洲公司 包含螯合剂的发酵培养基
AU2017386533B2 (en) * 2016-12-29 2024-05-09 Illumina, Inc. Analysis system for orthogonal access to and tagging of biomolecules in cellular compartments
US20190352609A1 (en) * 2017-01-05 2019-11-21 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Method for preparing reticulocyte simulating particles and platelet simulating particles, and reference control
US10745439B2 (en) * 2017-03-20 2020-08-18 Regents Of The University Of Minnesota Kinase substrates and methods of use thereof
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
JP7334178B2 (ja) * 2018-03-19 2023-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ＣＲＩＳＰＲ／Ｃａｓ系を使用した動物での転写モジュレーション
CA3120096A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
CN109627301B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin固体稳定剂开发及应用
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
SI4037666T1 (sl) 2020-12-08 2024-09-30 Ruminant Biotech Corp Limited Izboljšave naprav in postopkov za dostavo snovi živalim
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113121705B (zh) * 2021-04-19 2023-03-24 成都英普博集生物科技有限公司 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用
WO2024015366A1 (en) * 2022-07-11 2024-01-18 Arkea Bio Corp. Compositions and methods for reducing methane emissions in ruminant populations
WO2024097397A1 (en) * 2022-11-03 2024-05-10 Helix Nanotechnologies, Inc. Ruminal and methanogen vaccines and uses thereof
CN115938486B (zh) * 2022-12-06 2023-11-10 内蒙古农业大学 基于图神经网络的抗菌性乳酸菌株筛选方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159861A (en) * 1875-02-16 Improvement in brooms
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
ZA843277B (en) * 1983-05-03 1984-12-24 Ssm Int Chem Co Ltd A composition of improved pharmaceutical activity and utilization thereof for veterinary use
GB8815968D0 (en) * 1988-07-05 1988-08-10 Pfizer Ltd Veterinary devices
JPH05219927A (ja) * 1992-02-14 1993-08-31 Gumma Pref Gov 飼料の混合装置及び混合飼料の製造方法
JP3651915B2 (ja) * 1993-06-30 2005-05-25 財団法人神奈川科学技術アカデミー シグナル配列ペプチドをコードするｄｎａ断片の探索法及びそのためのベクター
ZA948204B (en) * 1993-10-19 1995-06-12 Commw Scient Ind Res Org Method for improving utilisation of nutrients by ruminant or ruminant-like animals
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
BR9506533A (pt) 1994-01-20 1997-09-16 Pastoral Agric Res Inst Nz Ltd Dispositivo para administração de materiais benéficos a ruminantes
NZ278977A (en) 1994-01-20 1997-03-24 Pastoral Agric Res Inst Nz Ltd Sustained release bolus for ruminants
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
AUPN353695A0 (en) 1995-06-14 1995-07-06 Commonwealth Scientific And Industrial Research Organisation Immunogenic preparation and method for improving the productivity of ruminant animals
WO1998007830A2 (en) * 1996-08-22 1998-02-26 The Institute For Genomic Research COMPLETE GENOME SEQUENCE OF THE METHANOGENIC ARCHAEON, $i(METHANOCOCCUS JANNASCHII)
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
AU2002326949A1 (en) 2001-09-18 2003-05-12 The Board Of Regents Of The University Of Nebraska Method for the inhibition of methanogenesis
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2003076575A2 (en) * 2002-03-04 2003-09-18 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
SE523209C2 (sv) * 2002-05-14 2004-04-06 Akzo Nobel Nv Förfarande för att reducera metanbildningen från matspjälkningsaktiviteter hos djur
WO2006102350A1 (en) 2005-03-23 2006-09-28 Washington University In St. Louis The use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
WO2009041832A2 (en) * 2007-09-25 2009-04-02 Pastoral Greenhouse Gas Research Ltd Vaccines and vaccine components for inhibition of microbial cells
CN101434924A (zh) * 2008-12-17 2009-05-20 中南大学 一种分离严格厌氧产甲烷古菌的方法
UY32866A (es) * 2009-08-27 2011-03-31 Pastoral Greenhouse Gas Res Ltd Secuencia genómica completa del metanógeno methanobrevibacter ruminantium
CN101864362B (zh) * 2010-05-19 2012-05-09 江苏加德绿色能源有限公司 一种复合微生物菌剂及其应用
DE102011119230B4 (de) * 2011-11-23 2013-07-11 Audi Ag Kraftwagen-Blinkleuchte und Verfahren zum Betreiben einer Blinkleuchte
EP2935364A2 (en) * 2012-12-21 2015-10-28 Danisco US Inc. Production of isoprene, isoprenoid, and isoprenoid precursors using an alternative lower mevalonate pathway

Also Published As

Publication number Publication date
MX2010003319A (es) 2010-09-10
JP6067209B2 (ja) 2017-01-25
EP3327030A1 (en) 2018-05-30
CA2700129C (en) 2021-07-20
UY31360A1 (es) 2009-04-30
JP2010539927A (ja) 2010-12-24
EP2203470A4 (en) 2011-04-13
US8586709B2 (en) 2013-11-19
NZ780936A (en) 2024-08-30
WO2009041832A3 (en) 2009-06-11
DK2203467T3 (en) 2017-03-27
UY31361A1 (es) 2009-04-30
WO2009041832A2 (en) 2009-04-02
EP3936516A1 (en) 2022-01-12
AU2008305846A1 (en) 2009-04-02
AR068551A1 (es) 2009-11-18
CA2700164C (en) 2018-05-29
CN107129524A (zh) 2017-09-05
CN101918431B (zh) 2014-10-08
CN107129524B (zh) 2023-11-21
DK3327030T3 (da) 2021-10-04
WO2009041830A3 (en) 2009-07-02
JP2017046704A (ja) 2017-03-09
EP3327030B1 (en) 2021-07-21
JP2010539928A (ja) 2010-12-24
CL2008002859A1 (es) 2009-03-06
CN102015755A (zh) 2011-04-13
CA2700162A1 (en) 2009-04-02
CN101932595A (zh) 2010-12-29
CA2700164A1 (en) 2009-04-02
CN101918431A (zh) 2010-12-15
RU2528854C2 (ru) 2014-09-20
BR122020023381B1 (pt) 2021-09-08
BRPI0817299A2 (pt) 2015-06-16
US20210332087A1 (en) 2021-10-28
WO2009041831A1 (en) 2009-04-02
JP5558356B2 (ja) 2014-07-23
EP2203467A1 (en) 2010-07-07
WO2009041832A9 (en) 2009-10-22
ES2895908T3 (es) 2022-02-23
BRPI0817312B1 (pt) 2018-05-29
EP2203470A2 (en) 2010-07-07
US10995120B2 (en) 2021-05-04
BR122021010737B1 (pt) 2021-09-21
AR068553A1 (es) 2009-11-18
AU2008304018A1 (en) 2009-04-02
WO2009041830A2 (en) 2009-04-02
US11926647B2 (en) 2024-03-12
RU2010116163A (ru) 2011-11-10
DK2203466T3 (en) 2016-07-25
BR122021010729B1 (pt) 2022-02-15
US10590170B2 (en) 2020-03-17
US20170342112A1 (en) 2017-11-30
BRPI0817299A8 (pt) 2019-01-29
US20200325180A1 (en) 2020-10-15
EP2203466B1 (en) 2016-04-06
JP5552053B2 (ja) 2014-07-16
NZ745324A (en) 2023-02-24
US8592556B2 (en) 2013-11-26
EP2203466A2 (en) 2010-07-07
US20140220636A1 (en) 2014-08-07
AU2014210649B2 (en) 2016-09-08
ZA201001933B (en) 2013-10-30
WO2009041831A9 (en) 2009-11-05
ES2587595T3 (es) 2016-10-25
AU2014210649A1 (en) 2014-09-04
EP2203466A4 (en) 2011-04-13
ES2625144T3 (es) 2017-07-18
AR068552A1 (es) 2009-11-18
US20100209999A1 (en) 2010-08-19
CN101932595B (zh) 2016-02-10
MX2010003328A (es) 2010-08-16
WO2009041830A9 (en) 2009-08-27
US9296789B2 (en) 2016-03-29
JP2015042166A (ja) 2015-03-05
UY31359A1 (es) 2009-04-30
CA2700129A1 (en) 2009-04-02
CA2700162C (en) 2018-08-14
EP2203467B1 (en) 2016-12-14
MX340736B (es) 2016-07-22
EP2203467A4 (en) 2011-04-13
US20100209998A1 (en) 2010-08-19
CL2008002861A1 (es) 2009-03-06
JP2010539926A (ja) 2010-12-24
MX2010003321A (es) 2010-08-03
US20100221185A1 (en) 2010-09-02
AU2008304019A1 (en) 2009-04-02
BRPI0817312A2 (pt) 2015-03-17

Similar Documents

Publication Publication Date Title
CL2008002860A1 (es) Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido.
CL2015001709A1 (es) Etiqueta de péptido que se une a hialuronano; ácido nucleico que la codifica; vector; célula hospedera; molécula etiquetada con dicho péptido; composición que la comprende; y método de producción de etiqueta de péptido.
CL2013002040A1 (es) Anticuerpo biespecifico o fragmento del mismo que se une especificamente a il-13 e il-14; molecula de acido nucleico que lo codifica; vector; celula; composicion farmaceutica; y sus usos (div.sol.n°3037-08).
CL2013002623A1 (es) Moleculas de union biespecificas que comprende al menos un componente que se une a vegf y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula.
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
CL2010001457A1 (es) Molecula de acido nucleico que codifica delta endotoxinas de bacillus thuringiensis; constituciones moleculares quer comprenden dichos polinucleotifdos, anticuerpos que se asocian especificamente a las endotoxinas, y procedimiento para el control de plagas de insectos.
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
CL2013000596A1 (es) Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf.
CL2009000379A1 (es) Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
BR112013005699A2 (pt) moléculas de ligação a 4-1bb
BR112016008125A2 (pt) moléculas de ligação de domínio de fibronectina tipo iii modificadas com cisteína
CL2013000669A1 (es) Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie.
CL2014000631A1 (es) Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
EA201171220A1 (ru) Мутанты fgf21 и их применение
AR070314A1 (es) Uso de peptidos de transito a plastidos derivados de glaucocystophytas
UA117575C2 (uk) Антитіло, яке специфічно зв'язується з il-17a та його застосування
EA201690946A1 (ru) Мутанты fgf21 и их применение
ECSP12011835A (es) Moléculas de unión biespecíficas para la terapia anti-angiogénesis.
CL2011001994A1 (es) Anticuerpo antagonista que se une a la proteína ox40 humana; secuencia de adn que lo codifica; vector de clonación o de expresión que comprende dicho adn codificante; célula huésped que comprende dicho vector de clonación o expresión; proceso de producción de dicho anticuerpo; composición farmacéutica que comprende a dicho anticuerpo; uso médico de dicho anticuerpo; proteína de fusión que comprende a dicho anticuerpo.
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2008001675A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-factorde crecimiento endotelial vascular (vegf); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion;antogonista de vegf que comprende el dab; composicion que comprende antogonista;y uso del antagonista para preparar un medicamento.
CL2012002879A1 (es) Proteína recombinante robo1-fc que comprende el dominio extracelular de la isoforma b de la proteína robo1 o una parte de este dominio, un conector y un dominio fc de una inmunoglobulina; molécula de ácido nucleico que la codifica; composición farmacéutica que la comprende; y su uso como herramienta de diagnóstico para detectar la sobreexpresión de una molécula de la familia slit en un paciente.
WO2009034190A3 (en) Affinity tag